PMID- 23092598
OWN - NLM
STAT- MEDLINE
DCOM- 20130107
LR  - 20211203
IS  - 1769-6917 (Electronic)
IS  - 0007-4551 (Linking)
VI  - 99
IP  - 10
DP  - 2012 Oct
TI  - [Non oncologic applications of molecular targeted therapies].
PG  - 953-62
LID - 10.1684/bdc.2012.1641 [doi]
AB  - Significant improvements in the knowledge of cancer biology have permitted the 
      development of new molecular targeted therapies. Meanwhile, a better 
      understanding of the physiology of various non-cancerous diseases has allowed 
      developing these agents in other areas. This review intends to illustrate these 
      perspectives through examples corresponding to different strategies of 
      molecular-targeted therapies : use of a monoclonal antibody binding a receptor 
      (rituximab and rheumatoid arthritis) or a ligand (bevacizumab and age-related 
      macular degeneration), tyrosine kinase inhibitor (imatinib and systemic 
      sclerosis) or inhibitor of cytoplasmic signal transduction pathways 
      (immunosuppressive and antiproliferative effects of mammalian target of rapamycin 
      [mTOR] inhibitors). Clinical results can draw today what could become molecular 
      medicine of tomorrow.
FAU - Khaled, Wassef
AU  - Khaled W
AD  - Groupe hospitalier Pitie-Salpetriere - Charles-Foix, service d'oncologie 
      medicale, Paris Cedex, France.
FAU - de la Motte Rouge, Thibault
AU  - de la Motte Rouge T
FAU - Amirault, Jean-Christophe
AU  - Amirault JC
FAU - Vignot, Stephane
AU  - Vignot S
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Applications therapeutiques non oncologiques des therapies moleculaires ciblees.
PL  - France
TA  - Bull Cancer
JT  - Bulletin du cancer
JID - 0072416
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Benzamides)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Piperazines)
RN  - 0 (Pyrimidines)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 8A1O1M485B (Imatinib Mesylate)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized/therapeutic use
MH  - Antibodies, Monoclonal, Murine-Derived/therapeutic use
MH  - Antirheumatic Agents/therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Benzamides
MH  - Bevacizumab
MH  - Drug-Eluting Stents
MH  - Humans
MH  - Imatinib Mesylate
MH  - Immunosuppressive Agents/therapeutic use
MH  - Macular Degeneration/*drug therapy
MH  - Molecular Targeted Therapy/*methods
MH  - Piperazines/therapeutic use
MH  - Protein-Tyrosine Kinases/antagonists & inhibitors
MH  - Pyrimidines/therapeutic use
MH  - Rituximab
MH  - Scleroderma, Systemic/*drug therapy
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors
EDAT- 2012/10/25 06:00
MHDA- 2013/01/08 06:00
CRDT- 2012/10/25 06:00
PHST- 2012/10/25 06:00 [entrez]
PHST- 2012/10/25 06:00 [pubmed]
PHST- 2013/01/08 06:00 [medline]
AID - S0007-4551(15)30392-1 [pii]
AID - 10.1684/bdc.2012.1641 [doi]
PST - ppublish
SO  - Bull Cancer. 2012 Oct;99(10):953-62. doi: 10.1684/bdc.2012.1641.